ZURICH (Reuters) – Novartis has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in preventing organ rejection, the Swiss group said on Friday.
Its study of the medicine in liver transplant continues, as do studies exploring it as a potential treatment in other conditions, it added in a statement https://www.novartis.com/news/novartis-announces-discontinuation-cirrus-1-study-cfz533-iscalimab-kidney-transplant-patients.
(Reporting by Michael Shields; Editing by Edmund Blair)
